(RTTNews) - GRI Bio, Inc. (GRI) Tuesday has priced its public offering at $3.60 per share, including Series Warrants, aiming to raise approximately $5 million before fees. The offering includes ...
GRI Bio’s lead program, GRI-0621, targets idiopathic pulmonary fibrosis, and the company is also developing treatments for systemic lupus erythematosus. While the company maintains strong liquidity ...
LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results